GNH USA

Europe — EMA

Irinotecano Aurovitas (Irinotecan Hydrochloride Trihydrate)

GNH USA supplies Irinotecano Aurovitas (Irinotecan), a topoisomerase I inhibitor for metastatic and advanced colorectal cancer. Request a quote for supply.

Irinotecan Hydrochloride Trihydrate

Request sourcing

1
Pack/s

What is Irinotecan Hydrochloride Trihydrate?

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecano Aurovitas, is a topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer and may be considered off‑label for small cell lung cancer.

GNH USA supplies Irinotecano Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Irinotecan Hydrochloride Trihydrate used for?

Irinotecano Aurovitas is used in colorectal cancer regimens and related oncologic pathways.

- Metastatic colorectal cancer: improves progression‑free and overall survival when combined with fluoropyrimidine‑based regimens. - Advanced colorectal cancer: incorporated into standard first‑line or second‑line chemotherapy protocols. - Small cell lung cancer (off‑label): may be considered in combination regimens for refractory disease.

What are the side effects of Irinotecan Hydrochloride Trihydrate?

Irinotecano Aurovitas may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Neutropenia - Alopecia - Fatigue - Abdominal pain

Serious or Rare Side Effects: - Severe neutropenia with fever (febrile neutropenia) - Life‑threatening diarrhea or colitis - Anaphylactic or severe allergic reactions - Hepatic toxicity (elevated transaminases) - Pulmonary toxicity (interstitial pneumonitis) - Significant electrolyte disturbances (e.g., hypokalemia).

What precautions apply to Irinotecan Hydrochloride Trihydrate?

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for toxicity.

- Dose adjustment: required for patients with hepatic impairment. - Renal function: monitor renal parameters despite primary hepatic clearance. - Myelosuppression: perform regular complete blood count monitoring. - Gastrointestinal toxicity: watch for early signs of severe diarrhea and intervene promptly. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Irinotecan Hydrochloride Trihydrate interact with?

Irinotecano Aurovitas can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure. - Concurrent use with other myelosuppressive agents: increased risk of severe neutropenia. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate constipation. - Drugs affecting bilirubin transport (e.g., atazanavir): may increase toxicity. - Warfarin: potential for altered INR and bleeding risk.

Frequently asked questions

What is Irinotecano Aurovitas used for?+
Irinotecano Aurovitas is an injectable chemotherapy product that contains irinotecan. It is approved for the treatment of metastatic and advanced colorectal cancer and is sometimes employed off‑label for small cell lung cancer when other options are limited.
How does Irinotecan work?+
Irinotecan is converted inside tumor cells to the active metabolite SN‑38, which inhibits topoisomerase I. This enzyme normally relaxes DNA during replication; its inhibition leads to persistent single‑strand breaks, triggering DNA damage and ultimately causing cancer cell death.
What is the usual dose of Irinotecano Aurovitas?+
The dosing regimen for Irinotecano Aurovitas is individualized. A qualified prescriber determines the dose, infusion schedule, and any dose modifications based on the patient’s clinical condition, body surface area, and organ function.
Is Irinotecano Aurovitas safe during pregnancy or breastfeeding?+
There are limited data on the use of irinotecan in pregnant or nursing individuals. Because the drug can cross the placenta and is excreted in breast milk, it is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant.
How do I order Irinotecano Aurovitas from GNH USA?+
To place an order, submit an enquiry on the Irinotecano Aurovitas product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.
How does Irinotecano Aurovitas compare with other colorectal cancer drugs?+
Irinotecan belongs to the topoisomerase I inhibitor class, offering a mechanism distinct from oxaliplatin (a platinum compound) or fluoropyrimidines. In combination regimens, irinotecan provides synergistic activity and is often used when tumors are resistant to or have progressed after oxaliplatin‑based therapy.
What are the storage and handling requirements for Irinotecano Aurovitas?+
The product must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Prior to use, it is reconstituted according to the manufacturer’s instructions and administered under aseptic conditions.
How is Irinotecano Aurovitas administered?+
Irinotecano Aurovitas is given by intravenous infusion. The reconstituted solution is infused over a specified period, typically ranging from 30 minutes to several hours, depending on the treatment protocol and patient tolerance.
What are the most serious risks associated with Irinotecano Aurovitas?+
The most critical adverse events include severe neutropenia with fever, life‑threatening diarrhea or colitis, and rare but serious allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential to reduce morbidity.
Who should not use Irinotecano Aurovitas?+
Patients with known hypersensitivity to irinotecan or any component of the formulation should avoid the product. Caution is also advised for individuals with severe hepatic impairment, uncontrolled infections, or those who are pregnant or breastfeeding unless the therapeutic benefit justifies the risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Irinotecan Hydrochloride Trihydrate
Route
Intravenous Use
Manufacturer
Eugia Pharma (Malta) Ltd
Origin
EU

Related products

Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer S.A.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Holding France
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Hellas A.E.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Healthcare Ireland Unlimited Company
EU